Medical Devices APAC

APAC Multi-Cancer Early Detection Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Multi-Cancer Early Detection Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $276.7 Mn Placeholder estimate
Estimate 2025 $348.9 Mn 18.6% of the global market
Projected 2034 $2.81 Bn 706.2% Adds $2.46 Bn over 9 forecast years
CAGR 2025–2034 26.1% Faster than 97% of 173 Medical Devices markets here
Key players 5
  • APAC is 18.61% of the global market.
  • Among regions, the largest is North America at $854.4 Mn.
  • Fastest growing: Africa at 26.9% a year.
  • APAC ranks 3rd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.46 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Multi-Cancer Early Detection Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $276.7 Mn — —
2025 (base) $348.9 Mn +$72.2 Mn —
2026 (forecast) $439.9 Mn +$91.1 Mn +26.1%
2027 (forecast) $554.7 Mn +$114.8 Mn +59%
2028 (forecast) $699.5 Mn +$144.8 Mn +100.5%
2029 (forecast) $882.1 Mn +$182.6 Mn +152.8%
2030 (forecast) $1.11 Bn +$230.2 Mn +218.8%
2031 (forecast) $1.40 Bn +$290.3 Mn +302.1%
2032 (forecast) $1.77 Bn +$366.1 Mn +407%
2033 (forecast) $2.23 Bn +$461.7 Mn +539.3%
2034 (forecast) $2.81 Bn +$582.1 Mn +706.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Multi-Cancer Early Detection Market Analysis at a glance
Market size, 2025$348.9 Mn placeholder estimate
Forecast, 2034$2.81 Bn placeholder estimate
Growth (CAGR), 2025–203426.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersGRAIL, Exact Sciences Corporation, Guardant Health, Inc., Freenome, Delfi Diagnostics (see all)
Active clinical trials23 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Multi-Cancer Early Detection Market Analysis Executive Summary

Multi-cancer early detection tests look for signs of many cancer types in one blood draw, before symptoms appear.

Key segments of the multi-Cancer Early Detection market include technology (Methylation Analysis, Fragmentomics and Protein Biomarkers) and setting (Primary Care, Employer Programs and Direct-to-Consumer).

Bar chart: Asia Pacific Multi-Cancer Early Detection market size, 2024–2034, placeholder estimates. $276.7 Mn in 2024, $348.9 Mn in 2025 and $2.81 Bn in 2034, 26.1% CAGR.
Asia Pacific Multi-Cancer Early Detection market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Multi-Cancer Early Detection Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the multi-Cancer Early Detection market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the multi-Cancer Early Detection market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the multi-Cancer Early Detection market, especially in low- and middle-income countries.

Competitive Landscape for Multi-Cancer Early Detection Market in APAC

The multi-Cancer Early Detection market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Multi-Cancer Early Detection Market in APAC

Multi-Cancer Early Detection in APAC: rules, payment and research

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 23 studies on Multi-Cancer Early Detection that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how multi-Cancer Early Detection products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Multi-Cancer Early Detection right now, from free public sources.

Clinical trials

23 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. GRAIL 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Multi-Cancer Early Detection in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Multi-Cancer Early Detection market in Asia Pacific?
Placeholder estimate: about $348.9 Mn in 2025, rising to about $2.81 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Multi-Cancer Early Detection market in Asia Pacific growing?
Placeholder estimate: about 26.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Multi-Cancer Early Detection market report cover?
The report splits the market by technology (Methylation Analysis, Fragmentomics, Protein Biomarkers), setting (Primary Care, Employer Programs, Direct-to-Consumer) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Multi-Cancer Early Detection market?
Key players include GRAIL, Exact Sciences Corporation, Guardant Health, Inc., Freenome and Delfi Diagnostics.
What is driving the Multi-Cancer Early Detection market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the multi-Cancer Early Detection market. Faster approvals and new combinations are improving survival.
How many clinical trials on Multi-Cancer Early Detection are running in Asia Pacific?
23 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Multi-Cancer Early Detection?
PubMed lists 234 papers on Multi-Cancer Early Detection added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on oncology and diagnostics and lab testing

See the topic